Bristol-Myers Squibb Evaluates KarXT for Bipolar-I Disorder Manic Episodes
A clinical trial is underway to assess the efficacy and safety of KarXT in treating manic episodes of Bipolar-I Disorder.
Asset / Drug
Drug and asset intelligence for Bristol-Myers with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.